Similar to CLL and AML, BCL-2 and BCL-XL overexpression was reported in acute lymphocytic leukemia (ALL), and in recent years, emerging preclinical and clinical reports have highlighted the potential efficacy of venetoclax and other BCL-2 family inhibitors in the treatment of ALL, including T-ALL, B-ALL, TCF3-HLF ALL and MLL-AF4 ALL [9,10,11]. Here, BCL2 is linked to acute myeloid leukemia.